Valve-in-valve transcatheter aortic valve replacement (TAVR) leads to lower device success compared to TAVR in native stenosis
ViV-TAVR for treatment of degenerated bioprostheses improves aortic valve function. However, device success is lower compared to TAVR in native aortic valve disease, mainly due to elevated postprocedural mean gradients, especially in small bioprostheses.
Authors
- Dominik Felbel (ORCID: https://orcid.org/0000-0003-0649-7364)
- Christian Liewald
- Marvin Krohn-Grimberghe (ORCID: https://orcid.org/0000-0002-5753-7330)
- Michael Paukovitsch (ORCID: https://orcid.org/0000-0002-8056-3908)
- Dominik Buckert (ORCID: https://orcid.org/0000-0001-6190-2145)
- Birgid Gonska (ORCID: https://orcid.org/0000-0002-1015-5853)
- L. Schneider
- Bartu Dilaver
- Johannes Moerike
Institutions
- Universität Ulm (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-04-22
- DOI
- https://doi.org/10.3389/fcvm.2025.1465409
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00